Pharmaceutical Care Division, King Faisal Specialist Hospital and Research Centre, MBC-11, P.O. Box 3354, Riyadh 11211, Saudi Arabia.
Pharmaceutical Care Division, King Faisal Specialist Hospital and Research Centre, MBC-11, P.O. Box 3354, Riyadh 11211, Saudi Arabia; Alfaisal University, College of Medicine, Riyadh, Saudi Arabia.
Can J Gastroenterol Hepatol. 2016;2016:2872371. doi: 10.1155/2016/2872371. Epub 2016 Apr 11.
Background and Aim. This is an open label prospective cohort study conducted at a tertiary care hospital. The primary endpoint is SVR12 in patients treated with sofosbuvir-based therapy in post-liver transplant patients with genotype 4 HCV recurrence. Methodology. Thirty-six treatment-experienced liver transplant patients with HCV recurrence received sofosbuvir and ribavirin ± peginterferon. Results. We report here safety and efficacy data on 36 patients who completed the follow-up period. Mean age was 56 years, and the cohort included 24 males and one patient had cirrhosis. Mean baseline HCV RNA was 6.2 log10 IU/mL. The majority of patients had ≥ stage 2 fibrosis. Twenty-eight patients were treated with pegylated interferon plus ribavirin in addition to sofosbuvir for 12 weeks and the remaining were treated with sofosbuvir plus ribavirin only for 24 weeks. By week 4, only four (11.1%) patients had detectable HCV RNA. Of the 36 patients, 2 (5.5%) relapsed and one died (2.75%). Conclusion. Our results suggest that sofosbuvir + ribavirin ± pegylated interferon can be utilized successfully to treat liver transplant patients with HCV recurrence.
背景和目的。这是一项在三级保健医院进行的开放标签前瞻性队列研究。主要终点是在基因型 4 HCV 复发的肝移植后患者中接受索非布韦为基础的治疗后 SVR12。方法。36 例治疗经验丰富的肝移植后 HCV 复发患者接受索非布韦和利巴韦林±聚乙二醇干扰素治疗。结果。我们在此报告了 36 例完成随访期的患者的安全性和疗效数据。平均年龄为 56 岁，队列包括 24 名男性和 1 名肝硬化患者。平均基线 HCV RNA 为 6.2log10IU/mL。大多数患者有≥2 期纤维化。28 例患者接受聚乙二醇干扰素加利巴韦林联合索非布韦治疗 12 周，其余患者接受索非布韦加利巴韦林治疗 24 周。治疗 4 周后，仅 4 例（11.1%）患者可检测到 HCV RNA。在 36 例患者中，2 例（5.5%）复发，1 例死亡（2.75%）。结论。我们的结果表明，索非布韦+利巴韦林±聚乙二醇干扰素可成功用于治疗 HCV 复发的肝移植患者。
